Didier Jc Bagnol

This inventor holds 4 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Arena Pharmaceuticals, Inc.. Active years: 2011-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Didier Jc Bagnol. Retrieved from https://idiyas.com/inventor/didier-jc-bagnol

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 2)

% Patents Active = 25.0

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 1.9

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

4 out of 218

Arena Pharmaceuticals, Inc.

patents

Years Active: 2011-2017

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9676758 - 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto (2017-06-13),

2. 9068983 - Methods of identifying candidate compounds of the human G protein-coupled receptor, GPR50, as modulators of body mass or adiposity (2015-06-30),

3. 8142762 - Methods of using GPR101 receptors to identify modulators of hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion (2012-03-27),

4. 7998685 - Methods of identifying candidate compounds of the human G protein-coupled receptor, GPR50, as modulators of body mass or adiposity (2011-08-16),

Title: The Innovative Contributions of Didier Jc Bagnol

Introduction

Didier Jc Bagnol is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target various disorders. With a total of 4 patents to his name, Bagnol's work is paving the way for new therapeutic approaches.

Latest Patents

Bagnol's latest patents include innovative compounds such as 1-heteroaryl-indoline-4-carboxamides, which serve as modulators of GPR52. These compounds are aimed at treating or preventing disorders related to GPR52 activity, including Huntington's disease, schizophrenia, and bipolar disorder. Another notable patent involves methods for identifying candidate compounds that modulate body mass or adiposity, which can be crucial in addressing obesity and related health conditions.

Career Highlights

Bagnol is currently associated with Arena Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work focuses on creating therapeutic agents that can effectively manage a range of disorders, thereby improving patient outcomes.

Collaborations

Throughout his career, Bagnol has collaborated with notable colleagues such as Chen Wang Liaw and Yifeng Xiong. These partnerships have enhanced the scope and impact of his research, leading to innovative solutions in the pharmaceutical industry.

Conclusion

Didier Jc Bagnol's contributions to the field of pharmaceuticals are noteworthy, as he continues to innovate and develop new treatments for complex disorders. His work exemplifies the importance of research and collaboration in advancing medical science.

Profile summary based on public USPTO records.